Axsome Therapeutics Aktie

96,56 EUR -0,12 EUR -0,12 %

08:05:38

FSE

107,13 USD -0,81 USD -0,75 %

nachbörslich03.04.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.4,85 Mrd. EUR

Div. Rendite0,00%

WKNA2AA7B

ISINUS05464T1043

SymbolAXSM

Axsome Therapeutics Aktien News

Sortieren:Datum Meistgelesen

26.11.23PR NewswireAXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

20.11.23PR NewswireROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM

14.03.23PR NewswireSHAREHOLDER ALERT: Axsome Therapeutics, Inc. (AXSM) Officers and Directors Face Shareholder Investigation for Alleged Securities Law Violations

WerbungAxsome Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

22.02.23GlobeNewswireAxsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

11.07.22PR NewswireSHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

11.07.22PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022

09.07.22PR NewswireAXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM

07.07.22PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

30.06.22PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

28.06.22PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

28.06.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

27.06.22PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022

20.06.22PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Axsome Investors of a Lead Plaintiff Deadline of July 12, 2022

20.06.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

09.06.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

03.06.22PR NewswireAXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022

31.05.22PR NewswireROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM

31.05.22PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

31.05.22PR NewswireAxsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

30.05.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

27.05.22PR NewswireAXSM SHAREHOLDER ALERT: Jakubowitz Law Reminds Axsome Shareholders of a Lead Plaintiff Deadline of July 12, 2022

26.05.22PR NewswireAxsome Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the...

24.05.22PR NewswireAXSM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 12, 2022 in the Class Action Filed on Behalf of Axsome Therapeutics, Inc. Shareholders

24.05.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Axsome Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AXSM

19.05.22PR NewswireAXSM LAWSUIT ALERT: Levi & Korsinsky Notifies Axsome Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

19.05.22PR NewswireAXSOME THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the...

18.05.22PR NewswireAxsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry

17.05.22PR NewswireShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm

16.05.22PR NewswireAxsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month

09.05.22PR NewswireJazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics

03.05.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM

02.05.22PR NewswireAxsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

02.05.22PR NewswireAxsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine

25.04.22PR NewswireAxsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022

Axsome Therapeutics News

Axsome Therapeutics News: auf dieser Seite finden Sie alle Axsome Therapeutics News und Nachrichten zur Axsome Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Axsome Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Axsome Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.